general conditions of use
privacy statement
imprint
© 2007 Bayer HealthCare Pharmaceuticals

 


Physician Support
Reimbursement Codes and Allowables
   
  reimbursement hotline 1-877-4VIADUR
Physician Office Codes

Approved codes* for Viadur®
Drug Code
2007 average allowable‡
CPT® code for insertion 11981
$115.53
CPT code for removal

11982

$134.59
CPT code for removal with insertion 11983 $200.68


Additional reimbursement for counseling and follow-up visits

CPT codes for follow-up visits*

Code

Physician presence required Typical length
of visit
Problem
presented
Requires 2 out of 3
of the following
2007 Medicare
Average Allowable
99211 No 5 min. Minimal   $20.09
  99212† Yes 10 min. Self-limited
or minor
—A problem focused history
—A problem focused examination
—Straightforward medical decision making
$36.76
  99213† Yes 15 min. Low to
moderate

—An examination problem focused history
—An expended problem focused examination
—Medical decision making of low complexity

$59.50
  99214† Yes 25 min. Moderate
to severe
—A detailed history
—A detailed examination
—Medical decision making of moderate complexity
$90.20
  99215† Yes 40 min. Moderate
to severe
—A comprehensive history
—A comprehensive examination
—Medical decision making of high complexity
$122.03
  • Counseling provided to patients at the time of implantation,
    reimplantation, or during follow-up visits may also be
    reimbursable using the appropriate CPT code*
  • Follow-up appointments should be scheduled at your discretion
    for regular examinations and to monitor your patients’ PSA

CPT is a registered trademark of the American Medical Association.

‡Average allowables as posted by CMS for the 1st quarter, January 1 - March 31, 2007. For more information visit www.cms.hhs.gov

*According to the American Medical Association’s Current Procedural Terminology 2004, a provider may bill Medicare for an office visit on the same day as a Viadur implant only if the decision to treat the patient with Viadur occurred during the office visit. When billing for an office visit on the same day as a Viadur implant, the office must attach a –25 modifier to the office visit. The –25 modifier indicates a significant, separate identifiable evaluation and management service (e.g., office visit) was performed by the same physician on the same day of a procedure and documented in the record. Because the office visit CPT codes vary based on time, complexity, and other factors, the provider will determine the appropriate office visit code based upon the content of the service provided.

†Counseling at the 99212 level or above requires that at least 2 out of 3 criteria for that level be met. See complete guidelines for process description.

For more details about Viadur® reimbursement, call 1-877-4VIADUR
Monday through Friday, 9:00 am to 5:00 pm EST


* Medicare Chart Book 3rd Edition Summer 2005 Section 3 page 22

Important Safety Considerations
Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur.

Viadur is contraindicated in women and pediatric patients and was not studied in women or children.

Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression.

The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).


Distributed and Marketed by:

Manufactured by:

Bayer HealthCare Pharmaceuticals
6 West Belt, Wayne, NJ 07470 USA

© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation.

The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.